Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence worldwide. Pathogenesis of MASLD has been considerably heterogenous. Increased hepatic de novo lipogenesis, adipose tissue dysfunction, genetic predisposition, epigenetic mechanism, and other related factors have been associate...
Kyung-Soo Kim, S. Lim, Cheol-Young Park· EXCLI Journal : Experimental...· 0 citations
Enavogliflozin showed a greater reduction in leptin than dapagliflozin, which persisted after adjustment for weight change, and changes in leptin correlated positively with changes in insulin, C-peptide, and HOMA-IR.
Y. Lyu, Kyung-Soo Kim, H. Lee et al.· Cardiovascular Diabetology· 0 citations
Aims Metabolic syndrome (MetS) is diagnosed using fixed thresholds that may not fully reflect the continuous accumulation of cardio-metabolic risk. We investigated whether whole blood viscosity (WBV) increases progressively with increasing MetS burden and explored the relative contribution of individual MetS components...
D. Lee, Byoungduck Han, Hongyup Ahn et al.· Frontiers in Endocrinology· 0 citations
BACKGROUND AND PURPOSE
Lobeglitazone is a thiazolidinedione and PPARγ agonist that improves metabolic parameters and hepatic steatosis, but its mechanisms are not fully understood. This study investigated the effects of lobeglitazone on hepatic transcriptomic and metabolic profiles in a rat model of obesity and Type 2...
Hyekyung Yang, S. Son, Youngmi Song et al.· British Journal of Pharmacol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.